Andrew Martin, MD
Infectious Disease · Margate, FLNPI 1740354950
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Melinta Therapeutics, LLC at 51.2% of the total. 2025 is the largest year on record at $3,929, more than ten times the $49 reported in 2019.
Across 173 payments — averaging $36.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$3K
- Viiv Healthcare Company$591
- Merck$544
- Shionogi Inc$511
- Insmed, Inc.$500
- AbbVie$340
- plus $586 from 10 others
Across 3 payments — averaging $35,776 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$104K
- Redhill Biopharma Inc.$4K
What the payments were for
- Speaking & faculty fees$2,51940%
- Travel & lodging$421%
- Food & beverage$3,70559%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 27 | $3,220 |
| Viiv Healthcare Company | 29 | $591 |
| Merck | 31 | $544 |
| Shionogi Inc | 22 | $511 |
| Insmed, Inc. | 24 | $500 |
| AbbVie | 14 | $340 |
| Paratek Pharmaceuticals, Inc. | 6 | $113 |
| Gilead | 5 | $110 |
| Cumberland Pharmaceuticals, Inc. | 3 | $90 |
| Aimmune Therapeutics, Inc. | 3 | $84 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| Pfizer | 2 | $41 |
| La Jolla Pharmaceutical Company | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| GSK | 1 | $19 |
| Exact Sciences | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rezzayo$2,757
How this compares
$6,291 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 15 | $102,323 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $73,030 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 16 | $62,992 |
| DovatoDolutegravir Sodium/Lamivudine | 20 | $59,393 |
| OzempicSemaglutide | 14 | $13,238 |
| ErtapenemErtapenem Sodium | 19 | $12,935 |
| Vancomycin Hcl | 44 | $7,132 |
| Bicillin L-APenicillin G Benzathine | 12 | $7,045 |
| Meropenem | 12 | $6,295 |
| CeftriaxoneCeftriaxone Sodium | 23 | $1,922 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 11 | $1,298 |
| Sodium Chloride0.9 % Sodium Chloride | 11 | $1,271 |
| Rifampin | 20 | $824 |
| Doxycycline Hyclate | 52 | $770 |
| Methenamine Hippurate | 12 | $603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $110 | $136,02233 claims |
| Viiv Healthcare CompanyDovato | $591 | $59,39320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Margate
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
- Sally AlrabaaTampa$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.